Multi-omic profiling provides insights into the heterogeneity, microenvironmental features, and biomarker landscape of small-cell lung cancer
This multimodal profiling analysis provides further insights into the biologic complexity of SCLC and highlights potential therapeutic vulnerabilities of distinct disease subtypes.
Authors
- Felix J. Segerer
- Jaime Rodriguez‐Canales (ORCID: https://orcid.org/0000-0002-0885-2377)
- Giulia Fabbri (ORCID: https://orcid.org/0000-0001-7690-8021)
- Markus Schick (ORCID: https://orcid.org/0009-0003-8626-0611)
- Alma Andoni (ORCID: https://orcid.org/0009-0006-2187-2790)
- Shashank Saran (ORCID: https://orcid.org/0009-0005-6212-8450)
- Miljenka Vuko (ORCID: https://orcid.org/0000-0001-8226-6352)
- Andrew G. Chambers (ORCID: https://orcid.org/0000-0001-7030-5780)
- Carl M. Gay (ORCID: https://orcid.org/0000-0002-4907-0718)
- Felicia Ng (ORCID: https://orcid.org/0000-0001-6335-711X)
- J. Carl Barrett (ORCID: https://orcid.org/0000-0003-4462-2955)
- Robert J. Cardnell (ORCID: https://orcid.org/0009-0005-6203-0234)
- Lauren A. Byers (ORCID: https://orcid.org/0000-0002-0780-2677)
- Helen K. Angell (ORCID: https://orcid.org/0000-0001-9822-4755)
- Hana Baakza (ORCID: https://orcid.org/0000-0002-8388-0554)
- Siyu Liu (ORCID: https://orcid.org/0000-0001-7089-2006)
- Mingchao Xie
- Paul Waring
Institutions
- AstraZeneca (United Kingdom) (GB)
- University of North Carolina at Chapel Hill (US)
- The University of Texas MD Anderson Cancer Center (US)
- AstraZeneca (France) (FR)
- AstraZeneca (Netherlands) (NL)
- AstraZeneca (Singapore) (SG)
- AstraZeneca (Japan) (JP)
- AstraZeneca (Finland) (FI)
- AstraZeneca (United States) (US)
- AstraZeneca (Germany) (DE)
Publication Details
- Journal
- Molecular Cancer
- Published
- 2025-12-02
- DOI
- https://doi.org/10.1186/s12943-025-02514-4
- Citations
- 2
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.09